Why Employers Keep Choosing the Wrong Pharmacy Benefit Managers

The current market for PBM services is heavily influenced by request-for-proposal processes that reward spreadsheet-ready figures rather than clinical outcomes. Renzo Luzzatti, CEO of US-Rx Care, argues that employers are conditioned to chase high percentage discounts that ultimately mask inflated drug prices and misaligned incentives. When a plan focuses on rebate guarantees, it often overlooks whether the PBM is steering members toward high-cost medications that generate revenue for the vendor rather than savings for the plan.

This administrative trap is significant, as the U.S. Department of Labor estimates that nearly 90 million Americans receive prescription benefits through employer-sponsored, self-insured plans. Many of these organizations believe they are running competitive searches, but their criteria often fail to address the fundamental conflict of interest inherent in the traditional PBM business model. Luzzatti warns that contractual language, such as 'claims fiduciary' clauses, frequently provides a false sense of security while stopping short of the legal obligations required under the Employee Retirement Income Security Act (ERISA).

To move toward a model of lowest net cost, employers must shift their focus to transparency and accountability. The most critical evaluation step is determining whether a PBM will accept full fiduciary responsibility—a standard that mandates acting solely in the interest of the plan and its participants. By scrutinizing whether a vendor profits from the drugs they manage or if they own the pharmacies they utilize, employers can begin to dismantle the opaque structures that have historically driven up healthcare spending.